Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies.

Sangro B, Maini CL, Ettorre GM, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Sciuto R, Pizzi G, Lastoria S; European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY).

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1721-1730. doi: 10.1007/s00259-018-3968-5. Epub 2018 Mar 7.

2.

Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer.

Jakobs TF, Paprottka KJ, Raeßler F, Strobl F, Lehner S, Ilhan H, Trumm CG, Fendler WP, Sommer W, Paprottka PM.

Eur Radiol. 2017 Jan;27(1):113-119. Epub 2016 Apr 8.

PMID:
27059858
3.

Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.

Fendler WP, Lechner H, Todica A, Paprottka KJ, Paprottka PM, Jakobs TF, Michl M, Bartenstein P, Lehner S, Haug AR.

J Nucl Med. 2016 Apr;57(4):517-23. doi: 10.2967/jnumed.115.165050. Epub 2016 Jan 7.

4.

Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27.

5.

Safety of Radioembolization with (90)Yttrium Resin Microspheres Depending on Coiling or No-Coiling of Aberrant/High-Risk Vessels.

Paprottka PM, Paprottka KJ, Walter A, Haug AR, Trumm CG, Lehner S, Fendler WP, Jakobs TF, Reiser MF, Zech CJ.

Cardiovasc Intervent Radiol. 2015 Aug;38(4):946-56. doi: 10.1007/s00270-015-1128-x. Epub 2015 May 20.

PMID:
25986465
6.

[Stabilization of the pelvic ring with photodynamic bone stabilization (IlluminOss™)].

Stumpf M, Kraus T, Plötz W, Jakobs TF.

Unfallchirurg. 2015 Mar;118(3):279-82. doi: 10.1007/s00113-015-2743-3. German.

PMID:
25783693
7.

Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Ilhan H, Paprottka PM, Jakobs TF, Heinemann V, Bartenstein P, Khalaf F, Ezziddin S, Hacker M, Haug AR.

Eur Radiol. 2015 Sep;25(9):2693-700. doi: 10.1007/s00330-015-3658-7. Epub 2015 Feb 28.

PMID:
25721320
8.

Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization.

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Mar;56(3):333-8. doi: 10.2967/jnumed.114.150565. Epub 2015 Feb 5.

9.

CT fluoroscopy-guided percutaneous fiducial marker placement for CyberKnife stereotactic radiosurgery: technical results and complications in 222 consecutive procedures.

Trumm CG, Häussler SM, Muacevic A, Stahl R, Stintzing S, Paprottka PM, Strobl F, Jakobs TF, Reiser MF, Hoffmann RT.

J Vasc Interv Radiol. 2014 May;25(5):760-8. doi: 10.1016/j.jvir.2014.01.004. Epub 2014 Feb 12.

PMID:
24529549
10.

Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.

Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, Boeck S, Haas M, Laubender RP, Heinemann V.

Oncology. 2014;86(1):24-32. doi: 10.1159/000355821. Epub 2013 Dec 21.

PMID:
24401529
11.

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31.

12.

Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.

Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators.

J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23.

PMID:
23707371
13.

Standards of practice in transarterial radioembolization.

Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF.

Cardiovasc Intervent Radiol. 2013 Jun;36(3):613-22. doi: 10.1007/s00270-013-0600-8. Epub 2013 Mar 20. No abstract available.

PMID:
23511991
14.

Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation.

Ashoori N, Bamberg F, Paprottka P, Rentsch M, Kolligs FT, Siegert S, Peporte A, Al-Tubaikh JA, D'Anastasi M, Hoffmann RT, Reiser MF, Jakobs TF.

Digestion. 2012;86(4):338-48. doi: 10.1159/000342813. Epub 2012 Nov 28.

15.

CT fluoroscopy-guided vertebral augmentation with a radiofrequency-induced, high-viscosity bone cement (StabiliT(®)): technical results and polymethylmethacrylate leakages in 25 patients.

Trumm CG, Jakobs TF, Stahl R, Sandner TA, Paprottka PM, Reiser MF, Zech CJ, Hoffmann RT.

Skeletal Radiol. 2013 Jan;42(1):113-20. doi: 10.1007/s00256-012-1386-5. Epub 2012 Mar 16.

PMID:
22422022
16.

CT fluoroscopy-guided percutaneous vertebroplasty in spinal malignancy: technical results, PMMA leakages, and complications in 202 patients.

Trumm CG, Pahl A, Helmberger TK, Jakobs TF, Zech CJ, Stahl R, Paprottka PM, Sandner TA, Reiser MF, Hoffmann RT.

Skeletal Radiol. 2012 Nov;41(11):1391-400.

PMID:
22286549
17.

Multimodality treatment with conventional transcatheter arterial chemoembolization and radiofrequency ablation for unresectable hepatocellular carcinoma.

Ashoori N, Paprottka P, Trumm C, Bamberg F, Kolligs FT, Rentsch M, Reiser MF, Jakobs TF.

Digestion. 2012;85(1):18-26. doi: 10.1159/000334714. Epub 2011 Dec 8.

PMID:
22156507
18.

Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.

Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF.

Cardiovasc Intervent Radiol. 2012 Apr;35(2):334-42. doi: 10.1007/s00270-011-0248-1. Epub 2011 Aug 17.

PMID:
21847708
19.

Changes in normal liver and spleen volume after radioembolization with (90)Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance.

Paprottka PM, Schmidt GP, Trumm CG, Hoffmann RT, Reiser MF, Jakobs TF.

Cardiovasc Intervent Radiol. 2011 Oct;34(5):964-72. doi: 10.1007/s00270-011-0217-8. Epub 2011 Jul 6.

PMID:
21748452
20.

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY).

Hepatology. 2011 Sep 2;54(3):868-78. doi: 10.1002/hep.24451. Epub 2011 Jun 30.

PMID:
21618574

Supplemental Content

Loading ...
Support Center